Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2007
01/18/2007US20070015734 Mao-b inhibitors useful for treating obesity
01/18/2007US20070015733 Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains
01/18/2007US20070015732 Adenosine receptor antagonists and methods of making and using the same
01/18/2007US20070015731 5,6-Di-substituted oxadiazolopyrazines and thiadiazolopyrazines as CXC-chemokine receptor ligands
01/18/2007US20070015730 [4-(tert-butyldimethylsilanyloxy)-3-oxobutyl]methylcarbamic acid tert-butyl ester; (R)-6,8-difluoro-3,4-dihydro-2H-1-benzopyran-3-amine; for the treatment of cardiovascular disorders such as hypertension and chronic heart failure
01/18/2007US20070015729 Conjugate of cyclodextrin and poly(oxyethylene), and process for preparation thereof
01/18/2007US20070015728 Metered-dose and safety and compliance packaging for systemic anticancer therapy
01/18/2007US20070015727 applying gacyclidine into ear for treating an inner ear disorder hearing loss, tinnitus
01/18/2007US20070015726 treating respiratory system disorders comprising administering purinergic receptor agonists such as P1-(2',3'-benzylacetal uridine 5'-) P3-(uridine 5'-) triphosphate; chronic obstructive pulmonary disease; bronchitis; emphysema; cystic fibrosis; dyskinesia; alpha 1 antitrypsin deficiency
01/18/2007US20070015725 2-azapurine compounds and their uses
01/18/2007US20070015723 Antiviral oligonucleotides having a conserved G4 core sequence
01/18/2007US20070015720 Modulation of endogenous AICAR levels for the treatment of diabetes and obesity
01/18/2007US20070015719 Nanoparticulate clarithromycin formulations
01/18/2007US20070015718 Diagnosis and management of infection caused by Chlamydia
01/18/2007US20070015717 E-4-[2-methyl-2-(1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphth-7-yl)-vinyl]-phenyl-2'-(4'methoxyphenyl)-1'-ethanone; cancer
01/18/2007US20070015716 Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
01/18/2007US20070015715 Method of treating cancer and neuropathic complications induced by chemotherapeutic agents using selective Bradykinin B1 receptor antagonists
01/18/2007US20070015714 Methods for treating FSH related conditions with GnRH antagonists
01/18/2007US20070015698 Treatment of skin, and wound repair, with thymosin beta 4
01/18/2007US20070015697 Enhanced ocular neuroprotection and neurostimulation
01/18/2007US20070015687 Synergistic pharmaceutical combination for the prevention or treatment of diabetes
01/18/2007US20070015686 Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells
01/18/2007US20070015258 Alpha-beta C4BP -type recombinant heteromultimeric proteins
01/18/2007US20070015234 Whole cell assay for inhibitors of cathepsin k
01/18/2007US20070015219 Specifically binds an MK61 polypeptide produced by immunizing an animal
01/18/2007US20070015217 Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of Alzheimer's disease
01/18/2007US20070015214 Methods for identifying compounds for regulating muscle mass or function using prostanoid IP receptors
01/18/2007US20070015205 Crystal structure of phosphodiesterase 5 and use thereof
01/18/2007US20070015183 Biomarkers for huntington's disease
01/18/2007US20070014887 Medicated chewing gum delivery system for nicotine
01/18/2007US20070014883 Method for treating osteoarthritis
01/18/2007US20070014882 Ellagic acid and anti-coagulant compound
01/18/2007US20070014876 Synergistic compositions and method for potentiating anti-oxidative activity
01/18/2007US20070014875 Novel drug delivery system for proton pump inhibitors and process thereof
01/18/2007US20070014866 Composition for improving the efficacy and reducing the side effects of omega 3 fatty acids, fish oils and cardiovascular and diabetic treatments
01/18/2007US20070014865 Chemically stable, dry-flow, low compact, dust free, soluble granules of phosphoroamidothioate prepared by a process of dry granulation by agitative balling
01/18/2007US20070014864 Novel pharmaceutical granulate
01/18/2007US20070014863 Method of controlling paticle size of retinoic acid nanoparticles coated with polyvalent metal inorganic salt and nanoparticles obtained by the controlling method
01/18/2007US20070014861 Treatment of proctitis
01/18/2007US20070014860 Treatment of esophagitis
01/18/2007US20070014857 Pharmaceutical formulation having a masked taste and method for the production thereof
01/18/2007US20070014856 Drugs for disintegration on polymer to make dispersion endothermic enthalpy of solution
01/18/2007US20070014851 Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
01/18/2007US20070014850 Process for the preparation of dispersible tablets of cephalexin
01/18/2007US20070014849 Use of ramoplanin to treat diseases associated with the use of antibiotics
01/18/2007US20070014846 Pharmaceutical compositions comprising fenofibrate and atorvastatin
01/18/2007US20070014845 Liposomal delivery vehicle for hydrophobic drugs
01/18/2007US20070014844 Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
01/18/2007US20070014843 Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
01/18/2007US20070014840 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
01/18/2007US20070014839 Decomposer film for transdermal patches
01/18/2007US20070014833 Treatment of eye disorders with sirtuin modulators
01/18/2007US20070014832 Therapeutic compositions and methods
01/18/2007US20070014830 Drug-releasing sinus stent
01/18/2007US20070014829 Biocatalytic and biomimetic generation of nitric oxide in situ at substrate/blood interfaces
01/18/2007US20070014827 Gamma-tocopherol therapy for restenosis prevention
01/18/2007US20070014820 Opioid formulations
01/18/2007US20070014819 Method of emulsifying phytosterol by natural saponin,emulsion prepared thereby and water dispersible phytosterol powder product
01/18/2007US20070014818 Liquid formulations with high concentration of human growth hormone (HGH) comprising 1,2-propylene glycol
01/18/2007US20070014798 Antibodies to dendritc cells and human dendritic cell populations and uses thereof
01/18/2007US20070014797 Method for treating Sjogren's syndrome
01/18/2007US20070014791 Rage-related methods and copositions for treating glomerular injury
01/18/2007US20070014768 Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
01/18/2007US20070014760 Enhanced recovery following ocular surgery
01/18/2007US20070014758 Packaging materials for ophthalmic lenses
01/18/2007US20070014757 Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
01/18/2007US20070014756 Composition and method for treating the gastro-intestinal tract
01/18/2007US20070014754 Functionalized dendritic polymers for the capture and neutralization of biological and chemical agents
01/18/2007US20070014752 Surface functionalization of polymeric materials
01/18/2007US20070014751 Novel spiro-quinuclidinyl derivatives for the treatment of central nervous system disorders
01/18/2007US20070014738 Particles for inhalation having sustained release properties
01/18/2007US20070014737 Administering quinine, chlorzoxazone, cyclobenzaprine, carisoprodol via vaporization
01/18/2007US20070014735 Buccal delivery system
01/18/2007US20070014734 Glucuronidated nebivolol metabolites
01/18/2007US20070014733 Hydroxylated nebivolol metabolites
01/18/2007US20070011904 Process for co-spray drying agents with dry silicified MCC
01/18/2007DE3915617B4 Verwendung einer ein Cyclosporin enthaltenden Zusammensetzung zur topischen Applikation Use of a composition containing a cyclosporin for topical application
01/18/2007DE19782294B4 Nicht-Steroide Liganden für den Estrogenrezeptor Non-steroidal ligands for the estrogen receptor
01/18/2007DE102005047945A1 Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Raynaud Phänomenen Use of activators of soluble guanylate cyclase for the treatment of Raynaud's phenomenon
01/18/2007DE102005033903A1 New perfluoroalkyl-containing metal complexes, useful for production of contrast agents for use in e.g. NMR and X-ray diagnostics, necrosis imaging and in radiodiagnostics and radiotherapy
01/18/2007DE102005033099A1 Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung New 1,4-benzothiazepine-1,1-Dioxidderivat with improved properties, process for its preparation, pharmaceuticals comprising this compound and its use
01/18/2007DE102005032781A1 Antibakterielle Amid-Markozyklen VII Antibacterial amide Marko cycles VII
01/18/2007DE102005032307A1 Oligomere freier Fettsäuren und diese enthaltende Arzneimittel Oligomers of free fatty acids and pharmaceutical compositions containing them
01/18/2007DE102005032268A1 Oligomere von Cholesterol und dessen Derivaten sowie diese enthaltende Arzneimittel Oligomers of cholesterol and its derivatives and pharmaceutical compositions containing them
01/18/2007DE102005031705A1 Mittel, enthaltend L-Carnitin oder L-Carnitinderivate und mindestens eine weitere Substanz ausgewählt aus Taurin und dessen Derivaten und mindestens einem Wirkstoff, erhältlich aus Pflanzen der Gattung Echinacea Compositions containing L-carnitine or L-carnitine derivatives and at least one further substance selected from taurine and its derivatives and at least one active ingredient, obtainable from plants of the genus Echinacea
01/18/2007DE102005030952A1 Verfahren zur Herstellung einer wässrigen Suspension und einer pulverförmigen Zubereitung eines oder mehrerer Carotinoide A process for preparing an aqueous suspension of a powdered preparation and one or more carotenoids
01/18/2007DE102005030524A1 Substituierte Chinolone II Substituted Quinolones II
01/18/2007CA2657090A1 Clear pharmaceutical aqueous microemulsion comprising propofol and process for preparation
01/18/2007CA2630087A1 Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
01/18/2007CA2621359A1 Polysaccharide produced by microorganism belonging to genus bifidobacterium
01/18/2007CA2618708A1 Therapeutic agent and treatment method for ameliorating uremia
01/18/2007CA2615938A1 Urea glucokinase activators
01/18/2007CA2615802A1 Sustained release pharmaceutical compositions for highly water soluble drugs
01/18/2007CA2615726A1 Indol-3-yl-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
01/18/2007CA2615319A1 Compositions for oral administration of sustained release glutathione, methods for their production and uses thereof
01/18/2007CA2615291A1 Heterocyclic janus kinase 3 inhibitors
01/18/2007CA2615147A1 Neuroprotective modulation of nmda receptor subtype activities
01/18/2007CA2615129A1 Carbamate compounds for use in treating neurodegenerative disorders
01/18/2007CA2615127A1 Methods of treating epileptogenesis
01/18/2007CA2615118A1 Pharmaceutical composition containing ppar.gamma. agonist